On July 17, Almazov Centre signed a Memorandum of Understanding (MoU) with Angioline Interventional Device, a Russian manufacturer of medical devices for interventional cardiology.
The MoU focuses on the projects and programmes relating to the prevention and treatment of NCDs as well as cooperation aimed at developing innovative treatment methods in Russia (search for ideas, prototyping, development testing, preclinical and clinical trials).
In the course of the joint work the parties intend to create informational and educational programmes for doctors in order to transfer international expertise in relevant areas for better quality of patient care (establishment of a simulation centre, participation in the development of Interventional Cardiology programme of the Russian Society of Cardiology, including the support of research and educational projects implemented jointly with the European Association of Percutaneous Cardiovascular Interventions). In addition, this cooperation involves participation in the establishment of innovative programmes to improve access to health care and support for particular regional programmes within the scope of a national medical research centre (organizational and methodological support, creation of nosological registries, support for population studies and publication activities).